1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Robert Zaczek new CSO at NeurOp

 
• By Gemma Sharman

Atlanta-based biopharmaceutical company NeurOp, which specialises in developing new medicines for central nervous system disorders, has appointed Dr Robert Zaczek chief scientific officer. Dr Zaczek most recently served as executive director of psychiatry drug discovery at Bristol-Myers Squibb, during which time he headed the joint research team that currently collaborates with NeurOp on its depression and neuropathic pain programmes.

Atlanta-based biopharmaceutical company NeurOp, which specialises in developing new medicines for central nervous system disorders, has appointed Dr Robert Zaczek chief scientific officer. Dr Zaczek most recently served as executive director of psychiatry drug discovery at Bristol-Myers Squibb, during which time he headed the joint research team that currently collaborates with NeurOp on its depression and neuropathic pain programmes.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.